M&A Deal Summary

Fluidic Sciences Acquires Sphere Bio

On September 2, 2025, Fluidic Sciences acquired life science company Sphere Bio from Amadeus Capital Partners

Acquisition Highlights
  • This is Fluidic Sciences’ 1st transaction in the Life Science sector.
  • This is Fluidic Sciences’ 2nd transaction in the United Kingdom.

M&A Deal Summary

Date 2025-09-02
Target Sphere Bio
Sector Life Science
Buyer(s) Fluidic Sciences
Sellers(s) Amadeus Capital Partners
Deal Type Add-on Acquisition

Target

Sphere Bio

Cambridge, United Kingdom
Sphere Bio is a life sciences tools company developing high-throughput single-cell analysis technologies using proprietary picodroplet microfluidics. Its Cyto-Mine® platforms accelerate biologics discovery, cell line development, and cell therapy research for global biopharma and biotech companies. Sphere Bio is based in Cambridge, United Kingdom.

Search 214,877 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Fluidic Sciences

Royston, United Kingdom

Category Company
Sector Medical Products
DESCRIPTION

Fluidic Sciences make protein interaction analysis easy and robust, by developing transformative in-solution technologies and accessible instruments that help scientists quickly and accurately understand how proteins truly interact. Fluidic Sciences is based in Royston, United Kingdom.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 2 of 2
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-05-20 Fluidic Analytics

Cambridge, United Kingdom

Fluidic Analytics designs develop and manufacture tools that seek to revolutionize the way proteins are characterized, allowing customers to understand the machinery of life. Fluidic Analytics was founded in 2013 and is based in Cambridge, United Kingdom.

Buy -

Seller(S) 1

SELLER

Amadeus Capital Partners

Investor Investor Investor Investor Investor


Category Venture Capital Firm
Founded 1997
PE ASSETS 1.3B USD
Size Large
Type Sector Focused
DESCRIPTION

Amadeus Capital Partners is an early late-stage investor in high growth European technology companies. Specific areas of interest include AI & machine learning, online consumer services, cybersecurity, digital health and medical technology, digital media, enterprise SaaS, fintech, and insurtech. Amadeus Capital Partners was formed in 1997 and is based in London, United Kingdom.


DEAL STATS #
Overall 26 of 26
Sector: Life Science M&A 3 of 3
Type: Add-on Acquisition M&A Deals 20 of 20
Country: United Kingdom M&A 15 of 15
Year: 2025 M&A 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2025-09-02 Congenica

Cambridge, United Kingdom

Congenica is a digital health company offering a clinical decision support platform for accelerated genomic data interpretation. Congenica software enables genomic medicine by integrating genetic data into healthcare, empowering clinicians to provide life-changing answers that transform the lives of individuals, patients, and their families. Congenica was founded in 2012 and is based in Cambridge, England.

Sell -